Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT07219927 · ClinicalTrials.gov registry record
Real-World Patient Experiences Using Continuous Subcutaneous Apomorphine Infusion (ONAPGOTM) in the United States:
A clinical trial of Parkinson Disease, sponsored by Supernus Pharmaceuticals.
- Recruiting
- Registry status
- 120
- Enrollment target
- 5
- Study locations
NCT07219927 is a study of Parkinson Disease that is actively recruiting participants, run by Supernus Pharmaceuticals. The registered enrollment target is 120 participants, below the 5,326-participant average among 297 other Parkinson Disease trials with a reported enrollment target (98% lower). The trial reports 5 study locations across 3 states.
The verdict
NCT07219927, a study of Parkinson Disease, is actively recruiting participants, sponsored by Supernus Pharmaceuticals.
- RECRUITING
- Registry status
- 120 participants
- Enrollment target
- 5
- Study locations
Study Summary
Real-World Participants Experiences Using Continuous Subcutaneous Apomorphine Infusion (ONAPGOTM) in the United States: A Prospective, Phase 4, Multicenter, Observational Study in Parkinson's Disease
Conditions Studied
Interventions
- OTHER Observational study
Study Locations (5)
California
- Parkinson's Disease and Movement Disorders Center - Orange County (South) - Aliso Viejo
- Parkinson's Disease and Movement Disorders Center - Orange County (North) - Irvine
- Parkinson's Research Centers of America - Palo Alto - Palo Alto
Florida
- Parkinson's Disease & Movement Disorders Center of Boca Raton - Boca Raton
New York
- Parkinson's Disease and Movement Disorders Center - Long Island - Commack
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 120 participants |
| Start Date | 2025-03-31 |
| Est. Completion | 2027-08-01 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT07219927
The ClinicalTrials.gov registry entry for NCT07219927 describes a study currently listed as recruiting, categorized as an unspecified phase. The registered enrollment target is 120 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 5,326-participant average among 297 other Parkinson Disease trials with a reported enrollment target (98% lower). The listed sponsor is Supernus Pharmaceuticals, which has 57 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Parkinson Disease appearing as the primary indexed condition, and to 1 intervention - of which Observational study is the first listed.
NCT07219927 reports 5 study locations spanning 3 distinct geographic areas - top geographies include California, Florida, New York.
Frequently Asked Questions
What is clinical trial NCT07219927 about?
NCT07219927 is a clinical study titled "Real-World Patient Experiences Using Continuous Subcutaneous Apomorphine Infusion (ONAPGOTM) in the United States:". Real-World Participants Experiences Using Continuous Subcutaneous Apomorphine Infusion (ONAPGOTM) in the United States: A Prospective, Phase 4, Multicenter, Observational Study in Parkinson's Disease
What is the current status of trial NCT07219927?
This trial is currently recruiting. The enrollment target is 120 participants. The study started on 2025-03-31. Estimated completion is 2027-08-01.
What conditions does trial NCT07219927 study?
This clinical trial studies the following conditions: Parkinson Disease.
What interventions are being tested in trial NCT07219927?
The interventions under investigation include: Observational study (OTHER).
Who is sponsoring clinical trial NCT07219927?
This trial is sponsored by Supernus Pharmaceuticals, which has 57 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT07219927 being conducted?
This trial has 5 study locations across California, Florida, New York. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Parkinson Disease
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Evaluation of Correlation Between Oculometric Measures and Clinical Assessment in Parkinson's Disease
RECRUITING · NA
-
Colonoscopic Detection of Phosphorylated Alpha-synuclein for Parkinson's Diagnosis
RECRUITING
-
University of Delaware Parkinson's Disease Registry
RECRUITING
-
Neocortical Microarchitecture of Executive Function
RECRUITING · NA
-
Modification of Threat Interpretation Bias to Reduce Anxiety in Neurodegenerative Movement Disorders (Aim 3)
RECRUITING · NA
-
Intranasal Insulin and Glutathione as an Add-On Therapy in Parkinson's Disease
RECRUITING · Phase 2
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.